Avatar Intervention for Cannabis Use Disorder in Individuals with Severe Mental Disorders: A Pilot Study.

addiction intervention cannabis use disorder mood disorder psychotic disorder relational therapy virtual reality therapy

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
29 Apr 2023
Historique:
received: 26 03 2023
revised: 22 04 2023
accepted: 27 04 2023
medline: 27 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Cannabis use disorder (CUD) is a complex issue, even more so when it is comorbid with a severe mental disorder (SMD). Available interventions are at best slightly effective, and their effects are not maintained over time. Therefore, the integration of virtual reality (VR) may increase efficacy; however, it has not yet been investigated in the treatment of CUD. A novel approach, avatar intervention for CUD, uses existing therapeutic techniques from other recommended therapies (e.g., cognitive behavioral methods, motivational interviewing) and allows participants to practice them in real-time. During immersive sessions, participants are invited to interact with an avatar representing a significant person related to their drug use. This pilot clinical trial aimed to evaluate the short-term efficacity of avatar intervention for CUD on 19 participants with a dual diagnosis of SMD and CUD. Results showed a significant moderate reduction in the quantity of cannabis use (Cohen's d = 0.611,

Identifiants

pubmed: 37240936
pii: jpm13050766
doi: 10.3390/jpm13050766
pmc: PMC10223054
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : IRSC Catayseur
ID : CRS-2021-118
Organisme : Services et recherches psychiatriques AD
ID : NA
Organisme : Fondation Lévesque
ID : NA

Références

Schizophr Res. 2021 Feb;228:229-234
pubmed: 33461022
Int J Methods Psychiatr Res. 2018 Mar;27(1):
pubmed: 29034525
Res Soc Work Pract. 2012 May;22(3):293-300
pubmed: 25484549
Psychiatry Res. 1988 Jan;23(1):99-110
pubmed: 3363019
Drug Alcohol Depend. 2006 Jun 9;83(1):42-8
pubmed: 16289930
Addiction. 2021 May;116(5):1000-1010
pubmed: 33160291
J Stud Alcohol Drugs. 2009 Jul;70(4):516-27
pubmed: 19515291
Nat Rev Dis Primers. 2021 Feb 25;7(1):16
pubmed: 33627670
Psychol Med. 2022 Aug;52(11):2001-2008
pubmed: 35855651
J Subst Abuse Treat. 2017 Oct;81:53-58
pubmed: 28847455
Clin Chem. 2002 Feb;48(2):301-6
pubmed: 11805011
J Affect Disord. 2020 Apr 1;266:258-262
pubmed: 32056886
Biol Psychiatry. 2005 Mar 15;57(6):594-608
pubmed: 15780846
J Affect Disord. 2021 Feb 15;281:467-475
pubmed: 33360749
Schizophr Res. 2018 Jul;197:176-181
pubmed: 29486956
Front Neurosci. 2020 Jan 10;13:1409
pubmed: 31998066
Schizophr Res. 2020 Oct;224:40-44
pubmed: 33183946
Addiction. 2012 Jun;107(6):1123-31
pubmed: 22151583
Clin Psychol Rev. 2017 Nov;57:195-207
pubmed: 28781153
Addict Behav. 2015 Oct;49:59-63
pubmed: 26047836
Health Aff (Millwood). 2016 Jan;35(1):12-9
pubmed: 26733696
Addict Behav. 2023 Apr;139:107578
pubmed: 36563480
J Subst Abuse Treat. 2019 Jan;96:26-32
pubmed: 30466545
Addiction. 2022 Jan;117(1):172-181
pubmed: 34142398
Psychol Addict Behav. 2014 Mar;28(1):154-62
pubmed: 23276315
Cochrane Database Syst Rev. 2019 Jan 28;1:CD008940
pubmed: 30687936
Psychiatr Serv. 2008 Mar;59(3):276-82
pubmed: 18308908
Cyberpsychol Behav Soc Netw. 2010 Apr;13(2):159-62
pubmed: 20528271
Can J Psychiatry. 2013 Nov;58(11):646-9
pubmed: 24246436
Indian J Psychiatry. 2003 Jul;45(3):182-8
pubmed: 21206852
Cyberpsychol Behav Soc Netw. 2014 Apr;17(4):262-7
pubmed: 24555521
Subst Use Misuse. 2022;57(5):719-729
pubmed: 35170396
Drug Alcohol Rev. 2020 May;39(4):337-346
pubmed: 32291811
Front Hum Neurosci. 2014 Oct 17;8:844
pubmed: 25368571
J Affect Disord. 2015 Jan 15;171:39-47
pubmed: 25285897
Psychopharmacol Bull. 2020 May 19;50(2):56-67
pubmed: 32508368
Adv Exp Med Biol. 2021;1264:67-80
pubmed: 33332004
Clin Psychol Rev. 2022 Dec;98:102213
pubmed: 36356351
Acta Psychiatr Scand. 2006 Aug;114(2):109-17
pubmed: 16836598
Addiction. 2022 Jul;117(7):1857-1870
pubmed: 35048456
Int J Drug Policy. 2021 Nov;97:103295
pubmed: 34062288
Int J Methods Psychiatr Res. 2020 Mar;29(1):e1813
pubmed: 31808250
Rev Mal Respir. 2014 Jun;31(6):488-98
pubmed: 25012035
Addiction. 2018 Oct;113(10):1905-1926
pubmed: 29749059
Drug Alcohol Depend. 2018 Oct 1;191:234-258
pubmed: 30153606
Psychiatr Serv. 2012 Jul;63(7):666-71
pubmed: 22588167
Neuropsychopharmacology. 2018 Jan;43(1):173-194
pubmed: 28875989
Health Promot Chronic Dis Prev Can. 2020 Jun;40(5-6):176-183
pubmed: 32529977
Psychiatr Serv. 2009 Jan;60(1):50-5
pubmed: 19114570
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005336
pubmed: 16856093
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Schizophr Res. 2013 Jan;143(1):138-42
pubmed: 23187069
Subst Abuse. 2018 Feb 28;12:1178221818760551
pubmed: 29531472
Neurosci Biobehav Rev. 2019 Aug;103:14-20
pubmed: 31121199
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):107-120
pubmed: 30564886
Cyberpsychol Behav. 2009 Oct;12(5):477-83
pubmed: 19817561
Psychother Psychosom. 2011;80(5):287-97
pubmed: 21646823
Nicotine Tob Res. 2015 Jul;17(7):796-802
pubmed: 25475087
Drug Alcohol Depend. 2012 Mar 1;121(3):247-52
pubmed: 21955364
Exp Clin Psychopharmacol. 2000 Nov;8(4):509-17
pubmed: 11127422
Psychol Med. 2017 Oct;47(14):2393-2400
pubmed: 28325167
Am J Drug Alcohol Abuse. 2022 Nov 2;48(6):631-643
pubmed: 36137273
Cureus. 2021 Jul 29;13(7):e16722
pubmed: 34513357
Addict Behav. 2013 Oct;38(10):2551-4
pubmed: 23793042
Addict Behav. 2023 Mar;138:107552
pubmed: 36413909
J Psychiatr Res. 2021 Nov;143:516-527
pubmed: 33248674
Eur Addict Res. 2021;27(6):413-427
pubmed: 33965941
Subst Use Misuse. 2022;57(9):1470-1477
pubmed: 35754378
Br J Psychiatry. 2006 May;188:439-48
pubmed: 16648530
PLoS One. 2015 Mar 04;10(3):e0118916
pubmed: 25738578
JAMA Psychiatry. 2019 Apr 1;76(4):426-434
pubmed: 30758486
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Addiction. 2010 Apr;105(4):615-25
pubmed: 20403014
Psychiatry Res. 2015 Dec 15;230(2):341-9
pubmed: 26388103
J Nerv Ment Dis. 2009 Jan;197(1):35-40
pubmed: 19155808
Lancet Psychiatry. 2020 Apr;7(4):344-353
pubmed: 32197092
Schizophr Bull. 1984;10(3):388-98
pubmed: 6474101
Neurosci Biobehav Rev. 2019 Jun;101:78-84
pubmed: 30974123
Addiction. 2006 Oct;101(10):1479-92
pubmed: 16968350
Front Psychiatry. 2022 May 12;13:842329
pubmed: 35633799
Restor Dent Endod. 2017 May;42(2):152-155
pubmed: 28503482
Psychiatry Res. 2022 Jan;307:114338
pubmed: 34922239
Addict Behav. 2009 Jun-Jul;34(6-7):520-5
pubmed: 19268481
Prev Med. 2017 Nov;104:13-23
pubmed: 28705601
NPJ Schizophr. 2021 Feb 12;7(1):9
pubmed: 33580033
Curr Opin Psychol. 2021 Oct;41:40-45
pubmed: 33714892
Addict Behav. 2006 Oct;31(10):1881-94
pubmed: 16516397
Behav Res Ther. 2015 Nov;74:18-24
pubmed: 26355646
J Subst Abuse Treat. 2006 Jun;30(4):291-5
pubmed: 16716843
Addict Behav. 2008 Jun;33(6):743-56
pubmed: 18282663
Complement Ther Med. 2020 Aug;52:102480
pubmed: 32951730
Clin Psychol Psychother. 2021 May;28(3):519-537
pubmed: 34048621

Auteurs

Sabrina Giguère (S)

Department of Psychiatry and Addictology, University of Montreal, Montreal, QC H3T 1J4, Canada.
Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.

Stéphane Potvin (S)

Department of Psychiatry and Addictology, University of Montreal, Montreal, QC H3T 1J4, Canada.
Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.

Mélissa Beaudoin (M)

Department of Psychiatry and Addictology, University of Montreal, Montreal, QC H3T 1J4, Canada.
Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.
Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada.

Laura Dellazizzo (L)

Department of Psychiatry and Addictology, University of Montreal, Montreal, QC H3T 1J4, Canada.
Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.

Charles-Édouard Giguère (CÉ)

Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.

Alexandra Furtos (A)

Department of Chemistry, University of Montreal, Montreal, QC H2V 0B3, Canada.

Karine Gilbert (K)

Department of Chemistry, University of Montreal, Montreal, QC H2V 0B3, Canada.

Kingsada Phraxayavong (K)

Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.
Services et Recherches Psychiatriques AD, Montreal, QC H1N 3V2, Canada.

Alexandre Dumais (A)

Department of Psychiatry and Addictology, University of Montreal, Montreal, QC H3T 1J4, Canada.
Research Center of the University Institute in Mental Health of Montreal, Montreal, QC H1N 3V2, Canada.
Services et Recherches Psychiatriques AD, Montreal, QC H1N 3V2, Canada.
Institut National de Psychiatrie Légale Philippe-Pinel, Montreal, QC H1C 1H1, Canada.

Classifications MeSH